Dergi makalesi Açık Erişim
Topcu, Beril Tas; Kaplan, Ozan; Pehlivan, Sibel Bozdag; Celebier, Mustafa; Oner, Levent
<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
<identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/278015</identifier>
<creators>
<creator>
<creatorName>Topcu, Beril Tas</creatorName>
<givenName>Beril Tas</givenName>
<familyName>Topcu</familyName>
<affiliation>Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, Ankara, Turkiye</affiliation>
</creator>
<creator>
<creatorName>Kaplan, Ozan</creatorName>
<givenName>Ozan</givenName>
<familyName>Kaplan</familyName>
<affiliation>Hacettepe Univ, Fac Pharm, Dept Analyt Chem, Ankara, Turkiye</affiliation>
</creator>
<creator>
<creatorName>Pehlivan, Sibel Bozdag</creatorName>
<givenName>Sibel Bozdag</givenName>
<familyName>Pehlivan</familyName>
<affiliation>Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, Ankara, Turkiye</affiliation>
</creator>
<creator>
<creatorName>Celebier, Mustafa</creatorName>
<givenName>Mustafa</givenName>
<familyName>Celebier</familyName>
<affiliation>Hacettepe Univ, Fac Pharm, Dept Analyt Chem, Ankara, Turkiye</affiliation>
</creator>
<creator>
<creatorName>Oner, Levent</creatorName>
<givenName>Levent</givenName>
<familyName>Oner</familyName>
<affiliation>Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, Ankara, Turkiye</affiliation>
</creator>
</creators>
<titles>
<title>Development Of An Rp-Hplc Method To Evaluate The Basic Characteristics Of Talazoparib-Loaded Plga Nanoparticles</title>
</titles>
<publisher>Aperta</publisher>
<publicationYear>2024</publicationYear>
<dates>
<date dateType="Issued">2024-01-01</date>
</dates>
<resourceType resourceTypeGeneral="Text">Journal article</resourceType>
<alternateIdentifiers>
<alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/278015</alternateIdentifier>
</alternateIdentifiers>
<relatedIdentifiers>
<relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.25135/jcm.2310.2937</relatedIdentifier>
</relatedIdentifiers>
<rightsList>
<rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
<rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
</rightsList>
<descriptions>
<description descriptionType="Abstract"><p>The use of poly (ADP -ribose) polymerase (PARP) inhibitors for cancer treatment has been reported previously. Talazoparib is a PARP inhibitor, and its solubility problems encouraged us to prepare talazoparib-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles for use in brain cancer models. To determine the encapsulation efficiency and release profile, a reversed -phase high-pressure liquid chromatography (RP-HPLC) method was developed and validated. A Shiseido 5 mu m C18 100 angstrom column (250 x 4.6 mm) was used with a flow rate of 1.0 mL/min. Isocratic elution was performed using an acetonitrile:phosphate buffer (100 mm, pH 6.25) (35:65 v/v) mixture. The injection volume was 5 mu L and UV detection was performed at 227 nm. The method was linear within the range from 0.1 to 12.5 mu g/mL. The encapsulation efficiency and release profile of the prepared formulation were analyzed using the developed RP-HPLC method, and it was found that the encapsulation efficiency was 65.17% +/- 0.50 and the release of the talazoparib was around 40% within 5 h and remained stable for 25 h. The RP-HPLC method developed in the present study can be adapted for further applications to determine talazoparib in its commercial formulations and proposed encapsulated drug delivery systems.</p></description>
</descriptions>
</resource>
| Görüntülenme | 0 |
| İndirme | 0 |
| Veri hacmi | 0 Bytes |
| Tekil görüntülenme | 0 |
| Tekil indirme | 0 |